OncoMyx Therapeutics

[On Demand]
Search General Info
Search Education
Search Partnering Companies
OncoMyx Therapeutics is developing multi-armed, IV-delivered, and precision medicine oncolytic immunotherapies. The company has the industry’s most experienced oncolytic virus development team, CEO Steve Potts was previously at Ignyta (acquired by Roche for $1.7B), and Mirati CEO Chuck Baum is Chairperson. OncoMyx is seeking a $50M+ series B/crossover financing.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Being developed for multiple oncology indications
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3 programs
Cofounder, CEO and Director
OncoMyx Therapeutics